20 completed, 10 active not recruiting, 7 recruiting, 7 terminated. 51 Phase 1, 14 Phase 2.
Follow Refractory Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-Cell Lymphoma trials Research Report on Refractory Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | University of Michigan Rogel Cancer Center | 12 | 2026-11-01 | 2026-11-12 |
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 37 | 2025-08-25 | 2026-04-20 |
| Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Recruiting | Yazeed Sawalha | 38 | 2025-04-02 | 2026-08-25 |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Recruiting | AIDS Malignancy Consortium | 20 | 2025-02-13 | 2026-07-10 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma RC19D2 cell injection - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 | Recruiting | Beijing Yongtai Ruike Biotechnology Company Ltd | 25 | 2023-09-05 | 2024-08-27 |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies BGB-21447 - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Terminated | BeOne Medicines | 51 | 2023-06-20 | 2026-07-14 |
| Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2023-04-01 | 2023-01-13 | |
| NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Completed | Fred Hutchinson Cancer Center | 27 | 2022-12-08 | 2026-09-21 |
| Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 32 | 2022-11-03 | 2026-11-12 |
| Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab Ociperlimab, Tislelizumab, Rituximab - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Completed | BeiGene | 53 | 2022-04-25 | 2025-09-15 |
| Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Active not recruiting | University of California, Davis | 36 | 2021-09-17 | 2026-10-26 |
| Copanlisib Plus Venetoclax in R/R DLBCL Copanlisib, Venetoclax - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 48 | 2021-09-08 | 2026-01-07 |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel - Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | NeoImmuneTech | 17 | 2021-07-29 | 2026-08-10 |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| A Phase I/II Study of Diffuse Large B-cell Lymphoma Rituximab Paclitaxel Ruxolitinib - Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | National Health Research Institutes, Taiwan | 74 | 2021-05-01 | 2021-04-23 |
| Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma Copanlisib, Gemcitabine, Carboplatin - Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | University of Washington | 12 | 2020-03-31 | 2023-06-29 |
Showing 20 of 51. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (51) · Lymphoma, Follicular (18) · Lymphoma, Mantle-Cell (16) · Lymphoma, B-Cell, Marginal Zone (12) · Leukemia, Lymphocytic, Chronic, B-Cell (11) · Lymphoma, B-Cell (11) · Lymphoma, Non-Hodgkin (11) · Burkitt Lymphoma (6) · Hodgkin Disease (3) · Lymphoma (2) · Lymphoma, T-Cell (2) · Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Waldenstrom Macroglobulinemia (2) · AIDS-Related Complex (1)
Hemic and Lymphatic Diseases (51) · Immune System Diseases (50) · Immunoproliferative Disorders (50) · Lymphatic Diseases (50) · Lymphoproliferative Disorders (50) · Neoplasms by Histologic Type (50) · Lymphoma (49) · Neoplasms (49) · Lymphoma, B-Cell (40) · Lymphoma, Non-Hodgkin (40) · Hematologic Diseases (14) · Disease Attributes (12) · Leukemia (12) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12)
Rituximab (13) · Cyclophosphamide (11) · Magnetic Resonance Spectroscopy (11) · CT-P10 (9) · Specimen Handling (9) · Biopsy (8) · ibrutinib (8) · Lenalidomide (7) · fludarabine (7) · Etoposide (6) · Leukapheresis (6) · Carboplatin (5) · Nivolumab (5) · fludarabine phosphate (5) · Ifosfamide (4)
Fred Hutchinson Cancer Center (7) · National Cancer Institute (NCI) (7) · City of Hope Medical Center (6) · David Bond, MD (2) · M.D. Anderson Cancer Center (2) · Roswell Park Cancer Institute (2) · AIDS Malignancy Consortium (1) · Academic and Community Cancer Research United (1) · BeOne Medicines (1) · BeiGene (1) · Beijing Yongtai Ruike Biotechnology Company Ltd (1) · Beth Christian (1) · Dana-Farber Cancer Institute (1) · Hackensack Meridian Health (1) · Icahn School of Medicine at Mount Sinai (1)
United States (46) · China (4) · Germany (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Canada (1) · Italy (1) · New Zealand (1) · Spain (1)
Jordan Gauthier (3) · Alex F Herrera (2) · David Bond, MD (2) · Kami Maddocks, MD (2) · Alexandre Hirayama (1) · Alexandre V. Hirayama, MD (1) · Alexey Danilov (1) · Andre Goy, MD (1) · Ariela Noy (1) · Beth A Christian (1) · Beth Christian, MD (1) · Catherine S Diefenbach (1) · Craig Sauter (1) · Elizabeth Budde (1) · Elizabeth Budde, MD, PhD (1)
PMID 34515338, PMID 27111235, PMID 29038338, PMID 29386196, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31331917, PMID 31648294, PMID 32967009, PMID 33786583, PMID 34666344, PMID 36618900, PMID 36631449, PMID 37339586, PMID 37470137, PMID 37632592, PMID 37774014, PMID 37903325, PMID 39333103, PMID 39820359, PMID 41595202, PMID 42389828
P50CA107399 (3), P30CA016058 (2), P30CA016672 (2), P30CA033572 (2), R01CA136551 (2), UM1CA186644 (2), UM1CA186717 (2), 2025 (1), K24CA201524 (1), P01CA229086 (1), P30CA008748 (1), P30CA015083 (1), P30CA015704 (1), P30CA016087 (1), P30CA069533 (1)